ALFA Finder| Revenue growth | 27.9% YoY in FY26; Q4 grew 15.7% YoY. |
|---|---|
| Margins | FY26 EBITDA margin 34.6%; expected to return to 37-38% levels. |
| Order book | 700 metric tons initial commercial orders for battery materials. |
| Demand visibility | Strong traction in LFP value chain; 42 customers in qualification pipeline. |
| Management confidence | High, citing strategic milestones in battery materials and nutrition platforms. |
Growth
FY26 Revenue grew 27.9% to ₹642.3cr; PAT increased 25.7% to ₹174.3cr. Specialty ingredients revenue surged 62% YoY.
Outlook
Commissioning 25,000 MT Phase 1 battery materials by April 2027; targeted revenue potential ₹1,600-1,800cr at 100k MT peak capacity.
Risks
Volatile raw material prices (phosphoric acid), LPG supply disruptions, and high working capital days (213 days).
Earnings Call filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,223.20
- Market cap
- ₹13,816 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 73.4×Sector 43.8×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 2.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma delivered record quarterly revenue led by its Pharma Food Nutrition (PFN) segment, though specialty ingredients face short-term headwinds from the pause of a government rice program.
Sudeep Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.
Sudeep Pharma Q2 FY27 Results: Net Profit ₹51.8 Cr, Up 10.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.8 Cr · +10.7% YoY
Sudeep Pharma Capacity Expansion
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
- manufacturing capacity
- 51200 MT
Sudeep Pharma Board Meeting Date
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
Sudeep Pharma Other Announcement
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.